ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

Reports Propose Stricter Rules To Protect Research Participants

October 11, 2002

In Brief: Deadline June 1 For New ACS Prevention Awards; Money Available To Fund Five More

April 11, 1980

NCI Must Build a Research Community In Pancreatic Cancer, Review Groups Says.

March 9, 2001

NCI Increases R01 Grant Payline From 12th to 15th Percentile.

June 29, 2007

In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month

August 14, 1992

GAO Report Finds Increase in Self-Referred Pathology Services

August 9, 2013